Yes, that could happen. I suspect it would start a bidding war though. I don't think that Pfizer would let it get away for $45m considering they were willing to pay Tacere potential milestones of $145m + royalties for just one drug candidate using ddRNAi. I do wonder why they have been so secretive about the future of TT-033. Also, Alnylam would not want a company with much bigger pockets than BLT to have their patents. Alnylam have in the past publicly tried to discredit ddRNAi, yet paradoxically cross licenced their tech with BLT. Why would a company agree to do this when others pay many hundreds of thousands for a licence for Alnylam's technology? Sounds kind of suspicious to me and the current allegations made by Tekmira regarding Alnylam theft of their technology and misuse of trade secrets leaves me to think that this company certainly is not to be trusted. Remember that the CSIRO are challenging the RNAi space, and many believe they will succeed. This would leave all monies currently going to Alnylam now going to BLT. This would leave Alnylam with a lot of cash, but worthless patents and no income. Could they afford to let it get away? They have over $300million in cash, I think they would see it as a necessary aquisition.
Whilst many would see a nearly 100% return on today's sp a good offer, many, including myself, would be dead set against it.
Add to My Watchlist
What is My Watchlist?